{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:13:06Z","timestamp":1790284386920,"version":"4.1.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":581,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"British Heart Foundation Centre of Research Excellence","award":["RE\/18\/6\/34217"],"award-info":[{"award-number":["RE\/18\/6\/34217"]}]},{"name":"Vera Melrose Heart Failure Research Fund"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Although much is known about the usefulness of heart failure (HF)-specific instruments for assessing patient well-being, less is known about the value of generic instruments for the measurement of health-related quality of life (HRQL) in HF. The aim of this study was to assess the relationship between the EuroQol 5-dimension 5-level (EQ-5D-5L) visual analogue scale (VAS) and index scores, clinical characteristics, and outcomes in patients with HF and the effect of dapagliflozin on these scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We performed a patient-level pooled analysis of the DAPA-HF and DELIVER trials, which investigated the effectiveness and safety of dapagliflozin in patients with HF and reduced ejection fraction (HFrEF) and mildly reduced\/preserved ejection fraction (HFmrEF\/HFpEF), respectively. Patients reporting higher (better) EQ-5D-5L VAS and index scores had a lower prevalence of comorbidities, including atrial fibrillation and hypertension, than patients with a worse score. They were also more likely to have better investigator-reported (New York Heart Association class) and patient-self-reported (Kansas City Cardiomyopathy Questionnaire) health status and lower median N-terminal pro-B-type natriuretic peptide levels. Compared to patients with the lowest scores (Q1), those with higher EQ-5D-5L VAS scores had better outcomes: the hazard ratio for the composite of cardiovascular death or worsening HF was 0.81 (95% confidence interval 0.72\u20130.91) in Q2, 0.74 (0.65\u20130.84) in Q3, and 0.62 (0.54\u20130.72) in Q4. The risk of each component of the composite outcome, and all-cause death, was also lower in patients with better scores. Similar findings were observed for the index score. Treatment with dapagliflozin improved both EQ-5D-5L VAS and index scores across the range of ejection fraction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both higher (better) EQ-5D-5L VAS and index scores were associated with better outcomes. Dapagliflozin treatment improved EQ-5D-5L VAS and index scores, irrespective of ejection fraction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3263","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T12:40:34Z","timestamp":1714740034000},"page":"1524-1538","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Dapagliflozin and Quality of Life Measured Using the EuroQol 5-Dimension Questionnaire in Patients with Heart Failure with Reduced and Mildly Reduced\/Preserved Ejection Fraction"],"prefix":"10.1093","volume":"26","author":[{"given":"Mingming","family":"Yang","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]},{"name":"Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kondo","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]},{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh","family":"Talebi","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran F.","family":"Docherty","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erasmus","family":"Bachus","sequence":"additional","affiliation":[{"name":"Late-Stage Development, Cardiovascular, Renal, and Metabolism, Biopharmaceuticals R&D AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University Medical Center , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore and Duke-National University of Singapore \u00a0","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[{"name":"Yale School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe A.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Universidad Nacional de C\u00f3rdoba , C\u00f3rdoba ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City , Kansas City, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital Rigshospitalet , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Medical University, Clinical Military Hospital , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"TIMI (Thrombolysis in Myocardial Infarction) Study Group, Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"2026010913060841700_ejhf3263-bib-0001","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010913060841700_ejhf3263-bib-0002","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913060841700_ejhf3263-bib-0003","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026010913060841700_ejhf3263-bib-0004","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026010913060841700_ejhf3263-bib-0005","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913060841700_ejhf3263-bib-0006","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026010913060841700_ejhf3263-bib-0007","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913060841700_ejhf3263-bib-0008","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.17219\/acem\/149728","article-title":"Phenotyping in heart failure with preserved ejection fraction: A key to find effective treatment","volume":"31","author":"Zawadzka","year":"2022","journal-title":"Adv Clin Exp Med"},{"key":"2026010913060841700_ejhf3263-bib-0009","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00059-022-05123-9","article-title":"Comorbidities in heart failure with preserved ejection fraction","volume":"47","author":"Deichl","year":"2022","journal-title":"Herz"},{"key":"2026010913060841700_ejhf3263-bib-0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ejhf.30","article-title":"Co-morbidities in patients with heart failure: An analysis of the European Heart Failure Pilot Survey","volume":"16","author":"van Deursen","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026010913060841700_ejhf3263-bib-0011","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ejhf.2962","article-title":"Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction","volume":"25","author":"Yang","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026010913060841700_ejhf3263-bib-0012","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"2026010913060841700_ejhf3263-bib-0013","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026010913060841700_ejhf3263-bib-0014","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/ehjqcco\/qcab014","article-title":"Predicting the EQ-5D utilities from the Kansas City Cardiomyopathy Questionnaire in patients with heart failure","volume":"7","author":"Thomas","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026010913060841700_ejhf3263-bib-0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ejhf.2154","article-title":"Quality of life in men and women with heart failure: Association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire","volume":"23","author":"Ravera","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913060841700_ejhf3263-bib-0016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s41687-020-00216-7","article-title":"Evaluation of the usefulness of EQ-5D as a patient-reported outcome measure using the Paretian classification of health change among patients with chronic heart failure","volume":"4","author":"Jonsson","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"2026010913060841700_ejhf3263-bib-0017","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"2026010913060841700_ejhf3263-bib-0018","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11136-005-4364-8","article-title":"Utility-based quality of life measures in Alzheimer's disease","volume":"15","author":"Naglie","year":"2006","journal-title":"Qual Life Res"},{"key":"2026010913060841700_ejhf3263-bib-0019","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jval.2010.08.002","article-title":"EQ-5D as a quality of life measure in people with dementia and their carers: Evidence and key issues","volume":"14","author":"Hounsome","year":"2011","journal-title":"Value Health"},{"key":"2026010913060841700_ejhf3263-bib-0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11136-014-0770-0","article-title":"The use of the EQ-5D as a measure of health-related quality of life in people with dementia and their carers","volume":"24","author":"Orgeta","year":"2015","journal-title":"Qual Life Res"},{"key":"2026010913060841700_ejhf3263-bib-0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17050","article-title":"Development of DEMQOL-U and DEMQOL-PROXY-U: Generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation","volume":"17","author":"Mulhern","year":"2013","journal-title":"Health Technol Assess"},{"key":"2026010913060841700_ejhf3263-bib-0022","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12955-022-02036-3","article-title":"Assessing the psychometric performance of EQ-5D-5L in dementia: A systematic review","volume":"20","author":"Keetharuth","year":"2022","journal-title":"Health Qual Life Outcomes"},{"key":"2026010913060841700_ejhf3263-bib-0023","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: The current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"key":"2026010913060841700_ejhf3263-bib-0024","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"2026010913060841700_ejhf3263-bib-0025","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1007\/s11136-017-1699-x","article-title":"Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients","volume":"26","author":"Po\u00f3r","year":"2017","journal-title":"Qual Life Res"},{"key":"2026010913060841700_ejhf3263-bib-0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-89289-0","volume-title":"Value sets for EQ-5D-5L: A compendium, Comparative Review & User Guide","author":"Devlin","year":"2022"},{"key":"2026010913060841700_ejhf3263-bib-0027","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jval.2015.02.003","article-title":"Determinants of utility based on the EuroQol five-dimensional questionnaire in patients with chronic heart failure and their change over time: Results from the Swedish Heart Failure Registry","volume":"18","author":"Berg","year":"2015","journal-title":"Value Health"},{"key":"2026010913060841700_ejhf3263-bib-0028","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017278","article-title":"Change of health-related quality of life over time and its association with patient outcomes in patients with heart failure","volume":"9","author":"Sepehrvand","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026010913060841700_ejhf3263-bib-0029","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12955-020-01368-2","article-title":"Mapping the Minnesota Living with Heart Failure Questionnaire (MLHFQ) to EQ-5D-5L in patients with heart failure","volume":"18","author":"Kularatna","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"2026010913060841700_ejhf3263-bib-0030","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: Rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913060841700_ejhf3263-bib-0031","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jchf.2021.11.006","article-title":"Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial","volume":"10","author":"Solomon","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026010913060841700_ejhf3263-bib-0032","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026010913060841700_ejhf3263-bib-0033","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ejhf.1548","article-title":"The Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: Baseline characteristics","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026010913060841700_ejhf3263-bib-0034","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s11136-020-02705-0","article-title":"Population norms of health-related quality of life in Moscow, Russia: The EQ-5D-5L-based survey","volume":"30","author":"Ho\u0142ownia-Voloskova","year":"2021","journal-title":"Qual Life Res"},{"key":"2026010913060841700_ejhf3263-bib-0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ehf2.12363","article-title":"Assessing health-related quality of life in heart failure patients attending an outpatient clinic: A pragmatic approach","volume":"6","author":"Gallagher","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026010913060841700_ejhf3263-bib-0036","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40273-020-00984-6","article-title":"Health state utilities of patients with heart failure: A systematic literature review","volume":"39","author":"Di Tanna","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"2026010913060841700_ejhf3263-bib-0037","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"2026010913060841700_ejhf3263-bib-0038","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/ejhf.2652","article-title":"Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: The DELIVER trial","volume":"24","author":"Ostrominski","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913060841700_ejhf3263-bib-0039","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/ejhf.2587","article-title":"Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): Baseline characteristics","volume":"24","author":"Mullens","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913060841700_ejhf3263-bib-0040","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.hrtlng.2022.08.010","article-title":"The role of a multidisciplinary heart failure clinic in optimization of guideline-directed medical therapy: HF-Optimize","volume":"57","author":"Diederich","year":"2023","journal-title":"Heart Lung"},{"key":"2026010913060841700_ejhf3263-bib-0041","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-8-13","article-title":"A review of health utilities using the EQ-5D in studies of cardiovascular disease","volume":"8","author":"Dyer","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"2026010913060841700_ejhf3263-bib-0042","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1007\/s11136-019-02300-y","article-title":"A comprehensive catalogue of EQ-5D scores in chronic disease: Results of a systematic review","volume":"28","author":"Van Wilder","year":"2019","journal-title":"Qual Life Res"},{"key":"2026010913060841700_ejhf3263-bib-0043","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.675523","article-title":"Health-related quality of life in patients with different diseases measured with the EQ-5D-5L: A systematic review","volume":"9","author":"Zhou","year":"2021","journal-title":"Front Public Health"},{"key":"2026010913060841700_ejhf3263-bib-0044","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12955-014-0123-2","article-title":"Change in health status in long-term conditions over a one year period: A cohort survey using patient-reported outcome measures","volume":"12","author":"Peters","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"2026010913060841700_ejhf3263-bib-0045","volume-title":"NICE DSU Technical Support Document 8: An introduction to the measurement and valuation of health for NICE submissions","author":"Brazier","year":"2011"},{"key":"2026010913060841700_ejhf3263-bib-0046","volume-title":"2020\u20132023 Value Assessment Framework","author":"Institute for Clinical and Economic Review","year":"2020"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/7\/1524\/65512586\/eurjhf_26_7_1524.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/7\/1524\/65512586\/eurjhf_26_7_1524.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:07:28Z","timestamp":1767982048000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/7\/1524\/8328735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,5,3]]},"published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3263","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"2024-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}